Study Summary
This trial is testing the effects of a new drug on sleep apnea patients.
- Obstructive Sleep Apnea
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 3 nights (treatment duration)
Trial Safety
Phase-Based Safety
Trial Design
5 Treatment Groups
LTM1201AZ
1 of 5
LTM1201AT
1 of 5
LTM1201AG
1 of 5
LTM1201AD
1 of 5
Placebo
1 of 5
Experimental Treatment
Non-Treatment Group
16 Total Participants · 5 Treatment Groups
Primary Treatment: LTM1201AZ · Has Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 70 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there current opportunities for individuals to join this experiment?
"The information posted on clinicaltrials.gov confirms that this research study is still actively recruiting candidates. The medical trial was first brought to light on March 1st 2019 and the details have recently been refreshed as of September 19th 2022." - Anonymous Online Contributor
What is the upper limit of participants in this research study?
"Affirmative. According to clinicaltrials.gov, this research initiative which first began on March 1st 2019 is still accepting participants. The study requires 16 individuals who can travel to the single allocated site in order for it to reach completion." - Anonymous Online Contributor
Is this research program open to elderly individuals?
"As per the inclusion criteria, eligible participants must be aged 18-70 years." - Anonymous Online Contributor
Who is eligible to partake in this experiment?
"This sleep disorder trial is enrolling 16 individuals aged 18-70 with a minimum AHI of 10 events/h during NREM supine slumber. Obstructive Sleep Apnea (OSA) must be diagnosed for admission." - Anonymous Online Contributor